A randomized phase II/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer

Journal of the National Cancer Institute

Volumn 107, Issue 12, 2015, Pages

  Sclafani, Francesco ^a   Kim, Tae Y ^b   Cunningham, David ^a   Kim, Tae W ^c   Tabernero, Josep ^d   Schmoll, Hans J ^e   Roh, Jae K ^f   Kim, Sun Y ^g   Park, Young S ^h,i   Guren, Tormod K ⁱ   Hawkes, Eliza ^a   Clarke, Steven J ^j   Ferry, David ^k   Frödin, Jan Erik ^l   Ayers, Mark ^m   Nebozhyn, Michael ^m   Peckitt, Clare ^a   Loboda, Andrey ^m   Mauro, David J ^m   Watkins, David J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Seoul National University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^f Yonsei University College of Medicine   (South Korea)

^g National Cancer Center   (South Korea)

^h Samsung Medical Center   (South Korea)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j Department of Microbiology and Infectious Diseases   (Australia)

^k NEW CROSS HOSPITAL   (United Kingdom)

^l KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^m MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; DALOTUZUMAB; IRINOTECAN; K RAS PROTEIN; MESSENGER RNA; PLACEBO; SOMATOMEDIN C; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN; SOMATOMEDIN C RECEPTOR;

ACNE; ADULT; AGED; ARTICLE; ASTHENIA; CANCER MORTALITY; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECTS; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; UPREGULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERGLYCEMIA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; UP-REGULATION;

EID: 84955418383     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv258     Document Type: Article

References (36)

1. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1(11):1311–1318.
2. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–345.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–1765.
4. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075.
5. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25(22):3230–3237.
6. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–762.
7. Scartozzi M, Giampieri R, Maccaroni E, et al. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. Ann Oncol. 2012;23(7):1706–1712.
8. Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012;18(2):221–223.
9. Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3(6):658–673.
10. Pollack M. The insulin and insulin-like growth factor receptor family in neo-plasia: an update. Nat Rev Cancer. 2012;12(3):159–169.
11. Burgaud JL, Baserga R. Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor. Exp Cell Res. 1996;223(2):412–419.
12. Hu YP, Patil SB, Panasiewicz M, et al. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Res. 2008;68(19):8004–8013.
13. Scartozzi M, Mandolesi A, Giampieri R, et al. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer. 2010;127(8):1941–1947.
14. Kaulfuss S, Burfeind P, Gaedcke J, Scharf JG. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther. 2009;8(4):821–833.
15. Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther. 2010;12(3):361–371.
16. Broussas M, Dupont J, Gonzalez A, et al. Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor. Int J Cancer. 2009;124(10):2281–2293.
17. Atzori F, Tabernero J, Cervantes A, et al. A phase I pharmacokinetic and phar-macodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2011;17(19):6304–6312.
18. Watkins DJ, Tabernero J, Schmoll HJ, et al. A phase II study of the anti-IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer. Presented at the American Society of Clinical Oncology Annual Meeting, Orlando, FL, May 29 - June 2, 2009.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst. 2000;92(3):205–216.
20. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213–226.
21. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6(1):1–12.
22. Langer CJ, Novello S, Park K, et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non–small-cell lung cancer. J Clin Oncol. 2014;32(19):2059–2066.
23. Robertson JF, Ferrero JM, Bourgeois H, et al. Ganitumab with either exemes-tane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol. 2013;14(3):228–235.
24. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011;29(34):4541–4547.
25. Ramalingam SS, Spigel DR, Chen D, et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non–small-cell lung cancer. J Clin Oncol. 2011;29(34):4574–4580.
26. Reidy DL, Vakiani E, Fakih MG, et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol. 2010;28(27):4240–4246.
27. Van Cutsem E, Eng C, Nowara E, et al. Randomized phase Ib/II trial of rilo-tumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res. 2014;20(16):4240–4250.
28. Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014;15(6):569–579.
29. Basu B, Olmos D, de Bono JS. Targeting IGF-1R: throwing out the baby with the bathwater? Br J Cancer. 2011;104(1):1–3.
30. Wilson S, Chia SK. IGF-1R inhibition: right direction, wrong pathway? Lancet Oncol. 2013;14(3):182–183.
31. Huang F, Xu L, Khambata-Ford S. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer. Clin Cancer Res. 2012;18(4):1156–1166.
32. Gualberto A, Hixon ML, Karp DD, et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer. 2011;104(1):68–74.
33. Buck E, Gokhale PC, Koujak S, et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): Rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther. 2010;9(10):2652–2664.
34. Donovan EA, Kummar S. Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol. 2008;66(2):91–98.
35. Vrieling A, Voskuil DW, Bosma A, et al. Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels. Growth Horm IGF Res. 2009;19(2):126–135.
36. Hong TS, Clark JW, Haigis KM. Cancers of the colon and rectum: identical or fraternal twins? Cancer Discov. 2012;2(2):117–121.